Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Idexx Laboratories (IDXX) · oqro.io/stocks/IDXX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Idexx Laboratories insider trading
Have Idexx Laboratories insiders bought shares recently?
No open-market purchase by an insider of Idexx Laboratories was filed in the last 90 days. The latest on record was on Aug 6, 2019.
How often do Idexx Laboratories insiders buy and sell shares?
Since 2006, Idexx Laboratories insiders reported 24 open-market purchases and 1,026 sales on Forms 4 and 5, with purchases in 10 different years, most recently 2019.
Who is selling Idexx Laboratories stock?
In the last 90 days, 5 insiders of Idexx Laboratories (IDXX) reported 22 open-market sales worth $28.6M in total on SEC Form 4. The largest seller by value was Jonathan Jay Mazelsky, with $17.7M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade IDXX?
Yes. Members of Congress disclosed 2 trades in Idexx Laboratories (IDXX) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. April McClain Delaney (MD06).
When does Idexx Laboratories report its next results?
Idexx Laboratories's next results are expected on Feb 1, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−1.9% (−$13.14) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $689.35 on Nov 20, 2025 to $676.21 on Nov 20, 2026 (−1.9%). Disclosed in this range: 52 insider trades, 1 pre-arranged insider sale, 2 Congress trades, and 112 13F position changes for 4 quarters ending in it.
$400$500$600$800$676.21
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 55 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in Westbrook, Maine.
Last 12 months
−1.9%
S&P 500 +5.7% over the same dates
Market value
$53.3B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.35M shares sold short (3.0% of shares outstanding), +22.0% vs the previous count, 4.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$1.21B
+9.9% vs the same quarter a year earlier
Free cash flow, last 12 months
$1.3B
This quarter $421M, a year earlier $371M
Net debt
$177M
Debt $375M, cash $198M, at Sep 30, 2026
Net income, last 12 months
$1.18B
Operating profit covers interest 43.5x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 2, 2026.
Since Nov 19, 2025, IDXX is down 3.0% and the index fund is up 4.1%: 7 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much IDXX moves
A usual day
±1.1%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
3.3%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−5.0%May 11, 2026
Largest one-day rise
+21.8%Nov 2, 2026
Deepest fall of the year
−34.2%From the close of Nov 25, 2025 to Sep 11, 2026.
Days of 5% or more
3Out of 252 sessions, in either direction.
Beta 0.8(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Red flags in its filings
Jan 13
Top officer leaving
“(the “Company” or “IDEXX”) of his intent to step down as the Company’s President and Chief Executive Officer effective as of May 12, 2026 (the “Transition Date”) and retire from the Company and the Company’s Board of the Directors (the “Board”) immediately following the Company’s annual meeting of shareholders in May 2027 (the “Retirement Date”).”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
On the public record for Idexx Laboratories over the 12 months to Nov 21, 2026: 1 executive contribution.
Insider buying and selling since 2006
Insiders of Idexx Laboratories reported 24 open-market purchases and 1,026 sales since 2006; purchases in 10 different years, most recently 2019.
Year
Bought
Sold
2026
—
$58.4M53×53 trades
2025
—
$50.1M31×31 trades
2024
—
$30.7M26×26 trades
2023
—
$51.9M44×44 trades
2022
—
$18.6M21×21 trades
2021
—
$113M117×117 trades
2020
—
$234M186×186 trades
2019
$602K2×2 trades
$92.5M72×72 trades
2018
$458K3×3 trades
$42.8M45×45 trades
2017
$450K2×2 trades
$59.6M54×54 trades
2016
$140K1×1 trade
$25.7M20×20 trades
2015
$73K1×1 trade
$20.7M31×31 trades
2014
$698K4×4 trades
$20.6M18×18 trades
2013
$267K3×3 trades
$61.4M37×37 trades
2012
—
$34.2M55×55 trades
2011
$485K1×1 trade
$39.1M47×47 trades
2010
$109K2×2 trades
$33.4M32×32 trades
2009
—
$6.93M21×21 trades
2008
—
$7.48M66×66 trades
2007
$564K5×5 trades
$17.5M36×36 trades
2006
—
$4.75M14×14 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last 30 days
Written by software from the filings listed below · Nov 21, 2026
Insiders. In the 30 days to Nov 21, 2026, insiders of Idexx Laboratories filed 0 open-market purchases and 21 open-market sales (about $27.4M, in 4 filings, by 4 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales. (Idexx Laboratories on OQRO)
Funds and stakes. Fund 13F filings recorded in the 30 days show 1 new or larger position and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for IDXX on the settlement date of Oct 30, 2026 was 2,354,117 shares (+22.02% on the previous report), about 4.45 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 5,393 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Idexx Laboratories filed a Form 8-K on Nov 2, 2026 (Item 2.02) that OQRO classes as: reported its results. The press release filed with it is titled: "IDEXX Laboratories Announces Third Quarter Results"
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 21, 2026, insiders of Idexx Laboratories filed 0 open-market purchases and 21 open-market sales (about $27.4M, in 4 filings, by 4 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales.
The largest sale: Sharon E. Underberg, EVP, GC & Corporate Secretary, about $4.37M, filed Nov 5, 2026.
Funds and stakes
Fund 13F filings recorded in the 30 days show 1 new or larger position and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for IDXX on the settlement date of Oct 30, 2026 was 2,354,117 shares (+22.02% on the previous report), about 4.45 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 5,393 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $14.6M for its principal executive officer, and an average of $3.06M for the other named executive officers.
Company reports, price and press
Idexx Laboratories filed a Form 8-K on Nov 2, 2026 (Item 2.02) that OQRO classes as: reported its results.
The press release filed with it is titled: "IDEXX Laboratories Announces Third Quarter Results"
Its announcing sentence reads: "IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced third quarter results."
Press coverage listed by Finnhub: "Here's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade Ago" (Yahoo, Nov 19, 2026).
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Idexx Laboratories filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 53 open-market sales (about $58.4M, in 11 filings, by 9 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 32 open-market sales (about $50.3M, in 14 filings). (Idexx Laboratories on OQRO)
Congress. Members of Congress filed 2 disclosures on Idexx Laboratories in the 12 months to Nov 19, 2026: 0 purchases and 2 sales, by 1 member. In the 12 months before that: 19 disclosures. The largest range: Rep. April McClain Delaney (MD06), $1,001 to $15,000, filed Feb 2, 2026.
Funds and stakes. Fund 13F filings recorded in the 12 months show 44 new or larger positions and 69 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for IDXX on the settlement date of Oct 30, 2026 was 2,354,117 shares (+22.02% on the previous report), about 4.45 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 5,393 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Idexx Laboratories filed a Form 8-K on Mar 26, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member. The company's own opening sentence of that report reads: "On March 24, 2026, IDEXX Laboratories, Inc. ('IDEXX') and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 20..."
Who holds it. 1,300 funds reported a stake in Idexx Laboratories in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (11.0% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (6.9% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (5.2% of the value reported).
Attention. The English Wikipedia article on Idexx Laboratories was read about 49 times a day in the 7 days to Nov 18, 2026, against a usual 46 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Idexx Laboratories filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 53 open-market sales (about $58.4M, in 11 filings, by 9 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 32 open-market sales (about $50.3M, in 14 filings).
The largest sale: Sharon E. Underberg, EVP, GC & Corporate Secretary, about $4.37M, filed Nov 5, 2026.
Congress
Members of Congress filed 2 disclosures on Idexx Laboratories in the 12 months to Nov 19, 2026: 0 purchases and 2 sales, by 1 member. In the 12 months before that: 19 disclosures.
The largest range: Rep. April McClain Delaney (MD06), $1,001 to $15,000, filed Feb 2, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 44 new or larger positions and 69 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for IDXX on the settlement date of Oct 30, 2026 was 2,354,117 shares (+22.02% on the previous report), about 4.45 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 5,393 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $14.6M for its principal executive officer, and an average of $3.06M for the other named executive officers.
Company reports, price and press
Press coverage listed by Finnhub: "How IDEXX Stock Is Engineered To Make Money For You" (Yahoo, Nov 7, 2026).
Press coverage listed by Finnhub: "Executive Vice President At IDEXX Laboratories Sells $2.74M Of Stock" (Benzinga, Nov 6, 2026).
Idexx Laboratories's share price rose 21.9% on Nov 2, 2026 (close $671.64, from $551.21), about 15 times its usual one-session change.
Around that move, the same day, the company's press release read: "IDEXX Laboratories Announces Third Quarter Results".
IDXX closed at $676.21 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $553.48 to $676.21, a change of +22.2%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
A filing or headline published around a price move is not proof that it caused the move; OQRO lists it as published.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Idexx Laboratories filed a Form 8-K on Mar 26, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On March 24, 2026, IDEXX Laboratories, Inc. ('IDEXX') and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 20..."
Idexx Laboratories filed a Form 8-K on Feb 13, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the 'Company') notice of her intention to retire from the Board of Directors (the 'Board') effective immediately following the Company’s 2026 Annual Mee..."
Idexx Laboratories filed a Form 8-K on Jan 13, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the 'Company' or 'IDEXX') of his intent to step down as the Company’s President and Chief Executive Officer effective as of May 12, 2026 (the 'Transi..."
Press coverage listed by Finnhub: "Here's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade Ago" (Yahoo, Nov 19, 2026).
Press coverage listed by Finnhub: "How IDEXX Stock Is Engineered To Make Money For You" (Yahoo, Nov 7, 2026).
Press coverage listed by Finnhub: "Executive Vice President At IDEXX Laboratories Sells $2.74M Of Stock" (Benzinga, Nov 6, 2026).
IDXX closed at $698.47 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $555.80 to $698.47, a change of +25.7%.
Who holds it
1,300 funds reported a stake in Idexx Laboratories in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (11.0% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (6.9% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (5.2% of the value reported).
Attention
The English Wikipedia article on Idexx Laboratories was read about 49 times a day in the 7 days to Nov 18, 2026, against a usual 46 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Idexx Laboratories's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Idexx Laboratories's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
8 certified in FY2026 Q3, vs 9 a year earlier. 8 positions in total, median offered wage $143K a year.
Application Analyst- Principal I · 1Application Architect II · 1SAP Business Warehouse (BW) and Data Application Developer · 1Scientist II · 1Scientist Research Sr. I · 1
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
People read Idexx Laboratories's Wikipedia article about 45 times a day over the last week, close to the 47 on a usual day of the three months before.
May 16, 2026Busiest day: 160 views on Nov 2, 2026Nov 20, 2026
Views of the article Idexx Laboratories, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Risk factors in the annual report
Latest annual report filed Feb 20, 2026, compared with the one filed Feb 21, 2025. Read the filing
All 24 risk factor headings match the year before, give or take wording.
Legal proceedings (Item 3)
Due to the nature of our activities, we are at times subject to pending and threatened legal actions that arise out of the ordinary course of business. In the opinion of management, based in part upon advice of legal counsel, the disposition of any such currently pending or threatened matters is not expected to have a material effect on our results of operations, financial condition, or cash flows. However, the results of legal actions cannot be predicted with certainty.
Source: SEC EDGAR, Form 10-K filed Feb 20, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Where the revenue comes from
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 20, 2026. Read the filing
By business segment
CAG$3.95B92%
+11% on the year before ($3.57B)
Water segment revenue$201M4.7%
+8.7% on the year before ($185M)
LPD$132M3.1%
+8.0% on the year before ($122M)
Total revenue$4.3B+10%
By product or service
Product revenue$2.54B59%
+13% on the year before ($2.25B)
Service revenue$1.76B41%
+7.0% on the year before ($1.65B)
Total revenue$4.3B+10%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 12,000 words.
We have included certain terms and abbreviations used throughout this Annual Report on Form 10-K in the “Glossary of Terms and Selected Abbreviations.” Description of Business Segments. We operate primarily through three business segments: diagnostic and information management-based products and services for the companion animal veterinary industry, which we refer to as the Companion Animal Group (“CAG”); water quality products (“Water”); and diagnostic products and services for livestock and poultry health and to measure the quality and safety of milk and improve producer efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Refer to “Part II, Item 8. Financial Statements and Supplementary Data, Note 3. Revenue and Note 17.
What the section covers (14 headings)
Companion Animal Group
Water
Livestock, Poultry and Dairy
CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS
Revenue Recognition
Income Taxes
RECENT ACCOUNTING PRONOUNCEMENTS
RESULTS OF OPERATIONS AND TRENDS
Effects of Certain Factors on Results of Operations
Twelve Months Ended December 31, 2025, Compared to Twelve Months Ended December 31, 2024
Non-Operating Items
LIQUIDITY AND CAPITAL RESOURCES
Source: SEC EDGAR, Form 10-K filed Feb 20, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Sources and Uses of Cash
Commitments, Contingencies and Guarantees
Short sale volume: 55.2% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 52.5%. FINRA daily files, to Nov 20, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Off-exchange trading: 43.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (30.3% on ATS, 13.1% with other brokers), close to its 26-week average of 41.9%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: INTELLIGENT CROSS LLC (13.0%), UBS ATS (12.2%), SIGMA X2 (11.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.